Antiplatelet Therapy for Acute Ischemic Stroke Patients With Thrombocytopenia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- 90-day Composite events
研究概览
简要总结
The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
详细描述
Antiplatelet therapy is widely used in non-cardiogenic AIS patients for secondary prevention. However, it may also increase the risk of bleeding complications, especially in patients with thrombocytopenia. The goal of this clinical trial is to test the safety and effectiveness of antiplatelet therapy in acute ischemic stroke (AIS) patients with thrombocytopenia. Participants will be prescribed antiplatelet agents and followed up for 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years old
- •Acute ischemic stroke or transient ischemic attack with onset < 7 days
- •The last blood routine test before enrollment indicates platelet count < 100 x 10^9 and > 30 x 10^9
排除标准
- •Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury
- •Indications for anticoagulation therapy, e.g. atrial fibrillation
- •Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past
- •Have or plan to receive CEA or CAS in the following 3 months
- •Life expectancy less than 1 year
- •Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding
- •Pregnant or lactating women
- •Individuals identified by researchers as unsuitable for participation in the study due to other reasons.
研究组 & 干预措施
Intervention
Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
干预措施: aspirin, clopidogrel, cilostazol, and dipyridamole (Drug)
结局指标
主要结局
90-day Composite events
时间窗: 90 days
Composite events including ischemic stroke, hemorrhagic stroke, myocardial infarction, major extracranial hemorrhage, and vascular death within 90 days after enrollment
次要结局
- 90-day myocardial infarction(90 days)
- 90-day non-major bleeding(90 days)
- 90-day ischemic stroke(90 days)
- 90-day all-cause death(90 days)
- 90-day hemorrhagic stroke(90 days)
- 90-day major extracranial hemorrhage(90 days)
- 90-day vascular death(90 days)
- Discharge mRS(Through hospitalization, an average of 7 days)